O
Olivier Colomban
Researcher at Claude Bernard University Lyon 1
Publications - 43
Citations - 427
Olivier Colomban is an academic researcher from Claude Bernard University Lyon 1. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 10, co-authored 27 publications receiving 269 citations. Previous affiliations of Olivier Colomban include HCL Technologies & University of Lyon.
Papers
More filters
Journal ArticleDOI
A critical review of the analytical approaches for circulating tumor biomarker kinetics during treatment.
R. Almufti,M. Wilbaux,Amit M. Oza,Emilie Henin,Gilles Freyer,Michel Tod,Olivier Colomban,Benoit You +7 more
TL;DR: Efforts should be made to standardize biomarker kinetic analysis methodologies to ensure the optimized development of novel serum biomarkers and avoid the pitfalls of traditional markers.
Journal ArticleDOI
Population pharmacokinetics and pharmacodynamics of cisplatinum during hyperthermic intraperitoneal chemotherapy using a closed abdominal procedure.
Eddy Cotte,Olivier Colomban,Jérôme Guitton,Brigitte Tranchand,Nawel Bakrin,François-Noël Gilly,Olivier Glehen,Michel Tod +7 more
TL;DR: The pharmacokinetics of cisplatinum during closed abdominal hyperthermic intraperitoneal chemotherapy (HIPEC) could be modeled with a 3‐compartment model using a population pharmacokinetic approach and is the basis of further studies.
Journal ArticleDOI
Predictive values of hCG clearance for risk of methotrexate resistance in low-risk gestational trophoblastic neoplasias
Benoit You,M. Pollet-Villard,L. Fronton,C. Labrousse,Anne-Marie Schott,Touria Hajri,Pascal Girard,Gilles Freyer,Michel Tod,Brigitte Tranchand,Olivier Colomban,Benjamin Ribba,Benjamin Ribba,D. Raudrant,J. Massardier,Sylvie Chabaud,François Golfier +16 more
TL;DR: In the second largest cohort of low-risk GTN patients reported to date, choriocarcinoma pathology and CL(hCG) < or =0.37 l/day were major independent predictive factors for MTX resistance risk.
Journal ArticleDOI
Predictors of prescription errors involving anticancer chemotherapy agents
Florence Ranchon,Céline Moch,Benoit You,Gilles Salles,Vérane Schwiertz,Nicolas Vantard,Emilie Franchon,Claude Dussart,Emilie Henin,Olivier Colomban,Pascal Girard,Gilles Freyer,Catherine Rioufol +12 more
TL;DR: The independent risk factors identified should be targeted for preventive measures in order to improve anticancer agent prescriptions and reduce the risk of medication errors.
Journal ArticleDOI
CA-125 ELIMination rate constant K (KELIM) Is A Marker Of Chemosensitivity In Patients With Ovarian Cancer: Results from the Phase II CHIVA trial
Benoit You,Benoit You,Patrick Robelin,Patrick Robelin,Michel Tod,Christophe Louvet,Jean-Pierre Lotz,Sophie Abadie-Lacourtoisie,Michel Fabbro,Christophe Desauw,Nathalie Bonichon-Lamichhane,Jean-Emmanuel Kurtz,Philippe Follana,M. Leheurteur,Francesco Del Piano,Gwenael Ferron,Gaëtan de Rauglaudre,Isabelle Ray-Coquard,Pierre Combe,Annick Chevalier-Place,Florence Joly,Alexandra Leary,Eric Pujade-Lauraine,Gilles Freyer,Gilles Freyer,Olivier Colomban +25 more
TL;DR: The tumor-primary chemosensitivity, assessed by the modeled CA-125 KELIM calculated during neoadjuvant chemotherapy, may be a major parameter to consider for decision-making regarding IDS attempt, and selecting patients for treatments meant to reverse the primary chemoresistance.